Report Sections

See All Reports

  • HP:0002591: Polyphagia
  • Pneumonia (312) Abnormality of the cardiovascular system (29) Neoplasm (27) Respiratory tract infection (27) Hypoxemia (22) Depressivity (21) Diabetes mellitus (19) Acute kidney injury (19) Abnormal lung morphology (19) Thromboembolism (17) Hypertension (16) Anosmia (14) Myocardial infarction (14) Abnormality of coagulation (14) Stroke (13) Pulmonary embolism (13) Arthritis (12) Leukemia (12) Interstitial pneumonitis (12) Autistic behavior (11) Mental deterioration (11) Deep venous thrombosis (10) Type II diabetes mellitus (10) Pulmonary obstruction (10) Crohn's disease (10) Abnormality of the kidney (9) Autism (9) Obesity (9) Congestive heart failure (9) Chronic pulmonary obstruction (9) Chronic pain (9) Rheumatoid arthritis (8) Abnormality of the liver (8) Respiratory distress (8) Pulmonary fibrosis (8) Colitis (8) Myocarditis (8) Carcinoma (8) Ulcerative colitis (8) Behavioral abnormality (7) Dementia (7) Infertility (7) Inflammation of the large intestine (7) Pulmonary insufficiency (7) Low levels of vitamin D (7) Neoplasm of the lung (7) Type I diabetes mellitus (7) Psychosis (6) Coronary artery atherosclerosis (6) Lymphoma (6) Abnormality of the gastrointestinal tract (6) Chronic kidney disease (6) Sepsis (6) Renal insufficiency (5) Lymphopenia (5) Gastroparesis (5) Immunodeficiency (5) Systemic lupus erythematosus (5) Breast carcinoma (5) Peripheral arterial stenosis (5) Allergy (5) Encephalopathy (4) Hepatic fibrosis (4) Cardiac arrest (4) Dysphagia (4) Asthma (4) Alzheimer disease (4) Osteoarthritis (4) Neoplasm of the pancreas (4) Autoimmunity (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Sleep apnea (4) Prostate cancer (4) Neoplasm of head and neck (4) Addictive behavior (4) Insomnia (4) Obsessive-compulsive behavior (3) Seizure (3) Cardiomyopathy (3) Weight loss (3) Fever (3) Migraine (3) Pulmonary arterial hypertension (3) Bronchiectasis (3) Obstructive sleep apnea (3) Colon cancer (3) Reduced factor VIII activity (3) Malnutrition (3) Knee osteoarthritis (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Arrhythmia (3) Fatigue (3) Endometriosis (3) Non-small cell lung carcinoma (3) Neuroendocrine neoplasm (3) Hypercoagulability (3) Schizophrenia (3) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormal heart morphology (2) Tachycardia (2) Angina pectoris (2) Gastroesophageal reflux (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Mutism (2) Headache (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Atherosclerosis (2) Hypoventilation (2) Myelodysplasia (2) Psoriasiform dermatitis (2) Paroxysmal atrial fibrillation (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Cystoid macular edema (2) Hemeralopia (2) Cutaneous melanoma (2) Arteritis (2) Glioblastoma multiforme (2) Cervix cancer (2) Pulmonary edema (2) Ovarian neoplasm (2) Angioedema (2) Mania (2) Neoplasm of the large intestine (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Hypogeusia (1) Conductive hearing impairment (1) Abnormality of the eye (1) Cataract (1) Amblyopia (1) Periodontitis (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Abnormality of the skin (1) Jaundice (1) Lymphedema (1) Angiokeratoma corporis diffusum (1) Keratoconjunctivitis (1) Spasticity (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic steatosis (1) Hepatic failure (1) Hepatocellular carcinoma (1) Premature birth (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Pancreatitis (1) Abnormality of blood and blood-forming tissues (1) Gout (1) Diarrhea (1) Anorexia (1) Esophageal varix (1) Hypothermia (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Encephalitis (1) Waddling gait (1) Increased intracranial pressure (1) Celiac disease (1) Biliary cirrhosis (1) Hypotension (1) Osteomyelitis (1) Squamous cell carcinoma (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Back pain (1) Low back pain (1) Muscular dystrophy (1) Neonatal death (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Coronary artery stenosis (1) Chronic lymphatic leukemia (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Abnormal anterior horn cell morphology (1) Amyotrophic lateral sclerosis (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Inflammatory abnormality of the skin (1) Sinus tachycardia (1) Bronchiolitis (1) Postprandial hyperglycemia (1) Hepatitis (1) Erythroid hypoplasia (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Small cell lung carcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Subdural hemorrhage (1) Endocarditis (1) Toxemia of pregnancy (1) Myositis (1) Vaginal neoplasm (1) Cellulitis (1) Self-injurious behavior (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0002591: Polyphagia

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (5)


    Name (Synonyms) Correlation
    drug867 Computer Based Response Training Weight Loss Intervention Wiki 0.71
    drug3319 Sustained attention Wiki 0.71
    drug1399 Generic Response Training Control Intervention Wiki 0.71
    Name (Synonyms) Correlation
    drug3960 media multi-task Wiki 0.71
    drug3642 Video Wiki 0.71

    Correlated MeSH Terms (4)


    Name (Synonyms) Correlation
    D006963 Hyperphagia NIH 1.00
    D063766 Pediatric Obesity NIH 0.29
    D001068 Feeding and Eating Disorders NIH 0.27
    Name (Synonyms) Correlation
    D009765 Obesity NIH 0.24

    Correlated HPO Terms (1)


    Name (Synonyms) Correlation
    HP:0001513 Obesity HPO 0.24

    Clinical Trials

    Navigate: Correlations   HPO

    There are 2 clinical trials


    1 Translational Neuroscience: Response Training for Obesity Treatment

    This project will test whether a food response training intervention produces lasting body fat loss, use objective brain imaging to examine the mechanism of effect of this treatment and investigate the generalizability of the training to non-training foods, and examine factors that should amplify intervention effects to provide a test of the intervention theory. This novel treatment represents a bottom-up implicit training intervention that does not rely on executive control, prolonged caloric deprivation, and expensive clinicians to deliver, like behavioral weight loss treatments that have not produced lasting weight loss. If this computer-based response training intervention produces sustained body fat loss in overweight individuals, it could be easily implemented very broadly at almost no expense, addressing a leading public health problem.

    NCT03375853
    Conditions
    1. Obesity
    2. Hyperphagia
    3. Feeding and Eating Disorders
    Interventions
    1. Behavioral: Computer Based Response Training Weight Loss Intervention
    2. Behavioral: Generic Response Training Control Intervention
    MeSH:Obesity Hyperphagia Feeding and Eating Disorders
    HPO:Obesity Polyphagia

    Primary Outcomes

    Description: Change in participant's body fat percentage

    Measure: Body Fat Change

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Secondary Outcomes

    Description: Eating disorder symptoms as measured with the Eating Disorder Diagnostic Interview

    Measure: Change in Eating Disorder Symptoms

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Description: Change in Dietary Restraint, Emotional Eating, and External Eating (aggregate score) as measured by the Dutch Eating Behavior Questionnaire

    Measure: Dietary Restraint, Emotional Eating, and External Eating

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Description: Chang in Disinhibited Eating as measured by the Three Factor Eating Questionnaire

    Measure: Change in Disinhibited Eating Behavior

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Description: Change in Eating When Not Hungry as measured by the Eating in the Absence of Hunger Questionnaire

    Measure: Change in Eating in the Absence of Hunger Behavior

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Description: Change in Problematic eating patterns associated with symptoms of addictive behaviors as measured by the Yale Food Addiction Scale

    Measure: Change in Food Addiction Behavior

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Description: Change in Physical Activity as measured by the Paffenberger Questionnaire

    Measure: Change in Physical Activity

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Description: Change in Substance use frequency (i.e., number of times per day) for alcohol of participants as measured by the Daily Drinking Questionnaire

    Measure: Change in Alcohol Use Behavior

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Description: Change in Substance use frequency (i.e., number of times per day) for common recreational drugs of participants as measured by the Daily Drug Taking Questionnaire

    Measure: Change in Substance Use Behavior

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Description: Change in Participant behavioral response to food pictures, and subjective palatability rating

    Measure: Change in Participant Ratings of Unhealthy Food Palatability

    Time: Baseline, 1 month

    Description: Change in Participant behavioral response to food pictures, and willingness to pay given dollar amounts (aggregate score) for the pictured food

    Measure: Change in Participant Ratings of Food Monetary Value

    Time: Baseline, 1 month

    Description: Change Participant food craving behaviors as measured by the Food Craving and Liking Scale

    Measure: Change in Food Craving and Liking Behavior

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Description: Change in Participant BMI using standard methods of calculation

    Measure: Change in Body Mass Index

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Description: Change in mean R-Peak Amplitude measured using three-lead ECG using PowerLab 8 Diagnostic Suite

    Measure: Change in mean R-Peak Amplitude

    Time: Baseline, 1 month, 3 months, 6 months, 12 months

    Description: Change in Heart Rate Variability measured using three-lead ECG using PowerLab 8 Diagnostic Suite

    Measure: Change in Heart Rate Variability

    Time: Baseline, 1 month, 3 months, 6 months, 12 months
    2 Media Multi-tasking and Cued Overeating: Assessing the Pathway and Piloting an Intervention Using an Attentional Network Framework

    Childhood obesity is a critical public health problem in the United States. One factor known to contribute to childhood obesity is excess consumption. Importantly, excess consumption related to weight gain is not necessarily driven by hunger. For example, environmental food cues stimulate brain reward regions and lead to overeating even after a child has eaten to satiety. This type of cued eating is associated with increased attention to food cues; the amount of time a child spends looking at food cues (e.g., food advertisements) is associated with increased caloric intake. However, individual susceptibility to environmental food cues remains unknown. It is proposed that the prevalent practice of media multi-tasking-simultaneously attending to multiple electronic media sources-increases attention to peripheral food cues in the environment and thereby plays an important role in the development of obesity. It is hypothesized that multi-tasking teaches children to engage in constant task switching that makes them more responsive to peripheral cues, many of which are potentially harmful (such as those that promote overeating). The overarching hypothesis is that media multi-tasking alters the attentional networks of the brain that control attention to environmental cues. High media multi-tasking children are therefore particularly susceptible to food cues, thereby leading to increased cued eating. It is also predicted that attention modification training can provide a protective effect against detrimental attentional processing caused multi-tasking, by increasing the proficiency of the attention networks. These hypotheses will be tested by assessing the pathway between media-multitasking, attention to food cues, and cued eating. It will also be examined whether it is possible to intervene on this pathway by piloting an at-home attention modification training intervention designed to reduce attention to food cues. It is our belief that this research will lead to the development of low-cost, scalable tools that can train attention networks so that children are less influenced by peripheral food cues, a known cause of overeating. For example, having children practice attention modification intervention tasks regularly (which could be accomplished through user-friendly computer games or cell phone/tablet apps) might offset the negative attentional effects of media multi-tasking.

    NCT03882957
    Conditions
    1. Attention Concentration Difficulty
    2. Obesity, Childhood
    Interventions
    1. Behavioral: Sustained attention
    2. Behavioral: media multi-task
    3. Other: Video
    MeSH:Pediatric Obesity Hyperphagia
    HPO:Polyphagia

    Primary Outcomes

    Description: Eye-tracking will be used to measure the amount of time spent looking at static food cues while participants play a media game on the computer. The amount time spent looking at a food cue is a measure how much attention was given to the food cue. The longer the looking time, the greater amount of attention.

    Measure: Amount of time spent looking at food cues while playing a media game

    Time: approximately 15 minutes post-intervention

    Description: The amount of kcals consumed of snack foods after participants have completed the intervention.

    Measure: Amount of snack foods consumed post-intervention

    Time: approximately 30 minutes post-intervention

    Description: This questionnaire measures the amount of media multi-tasking in a typical hour of media use, by asking respondents to report their interaction with 12 forms of media. The 12 different media forms are print media, television, computer-based video, music, non-musical audio, video or computer games, telephone and mobile phone, instant messaging, text messaging, email, web surfing, and other computer-based applications. For each activity, respondents indicate how often they concurrently use the other 11 media forms, using a 4-point scale: never (0), a little of the time (0.33), some of the time (0.67), and most of the time (1).

    Measure: Daily usual media multi-tasking

    Time: approximately 10 minutes prior to the intervention

    HPO Nodes


    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook